Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04745143 | Monotherapy of an NMDA Enhancer for Schizophrenia | PHASE2 | RECRUITING | 80 | — | — | Jan 1, 2018 | Dec 1, 2027 | Mar 24, 2026 | 1 | Taiwan |
| NCT04917302 | Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia | PHASE2 | RECRUITING | 60 | — | — | Oct 13, 2020 | Dec 1, 2026 | Feb 19, 2025 | 1 | Taiwan |
Assessment of overall symptoms. Minimum value: 30, maximum value:210, the higher scores mean a worse outcome.
Assessment of negative symptoms. Minimum value: 0, maximum value:100, the higher scores mean a worse outcome.
| Arm | Type | Description |
|---|---|---|
| NMDAE | EXPERIMENTAL | An NMDA enhancer |
| Placebo | PLACEBO_COMPARATOR | Placebo |
| NMDAE plus Anti-inflammatory Agent (AIFA) | EXPERIMENTAL | An NMDA enhancer plus a drug with anti-inflammatory property |
| NMDAE plus Placebo | PLACEBO_COMPARATOR | An NMDA enhancer plus Placebo |
| Name | Type | Description |
|---|---|---|
| NMDAE | DRUG | Use of an NMDA enhancer for the treatment of schizophrenia |
| Placebo Cap | DRUG | Use of placebo as a comparator |
| NMDAE plus AIFA | DRUG | Use of an NMDA enhancer plus a drug with anti-inflammatory property for the treatment of schizophrenia. |
| NMDAE plus Placebo Cap | DRUG | Use of an NMDA enhancer plus placebo as a comparator |
Inclusion Criteria: * Have a DSM-5 (American Psychiatric Association) diagnosis of schizophrenia * Refuse or are unable to tolerate antipsychotics due to poor response or adverse effects * PANSS total score ≥ 60 * Free of antipsychotic drugs for at least 1 week * Agree to participate in the study a...